RD305C
Phase 3
Completed
- Conditions
- Periarthritis scapulohumeralis
- Registration Number
- JPRN-jRCT2080223475
- Lead Sponsor
- CHUGAI PHARMACEUTICAL CO., LTD.
- Brief Summary
The efficacy and safety of consecutive 5 weekly intra-articular injections of NRD101 were comparable with comparator. It was confirmed that NRD101 was well tolerated in Chinese patients with periarthritis scapulohumeralis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 260
Inclusion Criteria
(1) Patients who have been diagnosed with periarthritis scapulohumeralis based on clinical conditions.
(2) Limitation of movement, signs and symptoms lasting for 12 or more weeks.
Exclusion Criteria
(1) Other diseases with shoulder joint dysfunctions, such as rotator cuff tear, acute calcific tendinitis.
(2) Patients not appropriate for pharmacotherapy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method